Contact

All Publications

  • Diagnostic and Therapeutic Updates in Leptomeningeal Disease. Current oncology reports Roy-O'Reilly, M. A., Lanman, T., Ruiz, A., Rogawski, D., Stocksdale, B., Nagpal, S. 2023

    Abstract

    PURPOSE OF REVIEW: Leptomeningeal disease (LMD) is a devastating complication of advanced metastatic cancer associated with a poor prognosis and limited treatment options. This study reviews the current understanding of the clinical presentation, pathogenesis, diagnosis, and treatment of LMD. We highlight opportunities for advances in this disease.RECENT FINDINGS: In recent years, the use of soluble CSF biomarkers has expanded, suggesting improved sensitivity over traditional cytology, identification of targetable mutations, and potential utility for monitoring disease burden. Recent studies of targeted small molecules and intrathecal based therapies have demonstrated an increase in overall and progression-free survival. In addition, there are several ongoing trials evaluating immunotherapy in LMD. Though overall prognosis of LMD remains poor, studies suggest a potential role for soluble CSF biomarkers in diagnosis and management and demonstrate promising findings in patient outcomes with targeted therapies for specific solid tumors. Despite these advances, there continues to be a gap of knowledge in this disease, emphasizing the importance of inclusion of LMD patients in clinical trials.

    View details for DOI 10.1007/s11912-023-01432-2

    View details for PubMedID 37256537

  • A case of MOG antibody disoorder with pontine involvement mimicking CLIPPERS and extensive transverse myelitis Keroles, M., Stocksdale, B., Ng, J., Ahadi, S., Dunn, J. LIPPINCOTT WILLIAMS & WILKINS. 2022

    View details for Web of Science ID 000894020500090

  • Neuro-Oncology Practice Clinical Debate: long-term antiepileptic drug prophylaxis in patients with glioma. Neuro-oncology practice Stocksdale, B., Nagpal, S., Hixson, J. D., Johnson, D. R., Rai, P., Shivaprasad, A., Tremont-Lukats, I. W. 2020; 7 (6): 583–88

    Abstract

    Patients with primary brain tumors often experience seizures, which can be the presenting symptom or occur for the first time at any point along the illness trajectory. In addition to causing morbidity, seizures negatively affect independence and quality of life in other ways, for example, by leading to loss of driving privileges. Long-term therapy with antiepileptic drugs (AEDs) is the standard of care in brain tumor patients with seizures, but the role of prophylactic AEDs in seizure-naive patients remains controversial. In this article, experts in the field discuss the issues of AED efficacy and toxicity, and explain their differing recommendations for routine use of prophylactic AEDs.

    View details for DOI 10.1093/nop/npaa026

    View details for PubMedID 33312673

  • SECOND GENERATION BRAF/MEK INHIBITION IN ANAPLASTIC PLEOMORPHIC XANTHROASTROCYTOMA Stocksdale, B., Liao, Y., Coffey, G., Nagpal, S. OXFORD UNIV PRESS INC. 2020: 117–18

    View details for Web of Science ID 000590061300491